Okyo Pharma LTD Schedule 13G passive stakes

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in OKYO Pharma Ltd, signaling a full exit from their position.

Woodline Partners LP has disclosed beneficial ownership of 7.0% of OKYO Pharma LTD's ordinary shares, holding 3,652,190 shares.

Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 7.7% of OKYO Pharma Ltd's ordinary shares as of March 31, 2026.

Jorey Chernett has filed an amended Schedule 13G, disclosing a 9.45% beneficial ownership stake in OKYO Pharma Ltd.

Dauntless Investment Group, LLC reports a 1.17% passive ownership stake in OKYO Pharma Ltd. as of December 31, 2025.

Jorey Chernett has filed an amendment to Schedule 13G, reporting beneficial ownership of 7.76% of OKYO Pharma Ltd's common stock as of September 30, 2025.

Dauntless Investment Group, LLC has reported a 6.3% passive beneficial ownership stake in OKYO Pharma Ltd, totaling 2,422,048 common shares.

Laura Natalia Monica Fonda has disclosed a 5.01% passive ownership stake in OKYO Pharma Ltd, holding 1,928,451 common shares.

Dauntless Investment Group, LLC has disclosed a 7.3% passive ownership stake in OKYO Pharma Ltd, holding 2,735,780 common shares.

Jorey Chernett has reported a beneficial ownership of 6.75% of OKYO Pharma Ltd's common stock, totaling 2,301,300 shares, as of May 23, 2025.

Dauntless Investment Group, LLC has filed a Schedule 13G, disclosing a passive beneficial ownership of 1,999,380 common shares, representing 5.87% of OKYO Pharma Ltd.